


PHARMACEUTICAL 2021

VistaGen® Therapeutics

Vistagen Therapeutics Inc. Rank 377 of 402





PHARMACEUTICAL 2021



Vistagen Therapeutics Inc. Rank 377 of 402

The relative strengths and weaknesses of Vistagen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vistagen Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 111% points. The greatest weakness of Vistagen Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 286% points.

The company's Economic Capital Ratio, given in the ranking table, is -355%, being 402% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	1,580
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,771
Liabilities, Non-Current	8,730
Other Assets	3,982
Other Compr. Net Income	0
Other Expenses	2.6
Other Liabilities	0
Other Net Income	30
Other Revenues	0
Property and Equipment	210
Research and Development	13,374
Selling, General and Administrative Expense	7,427

Output Variable	Value in 1000 USD
Assets	5,772
Liabilities	11,502
Expenses	20,804
Revenues	0
Stockholders Equity	-5,729
Net Income	-20,774
Comprehensive Net Income	-20,774
Economic Capital Ratio	-355%

